tiprankstipranks
Advertisement
Advertisement

INMB Stock Latest News

INmune Bio announces new preclinical data for INB03
The FlyINmune Bio announces new preclinical data for INB03
18h ago
INMB
Inmune Bio Earnings Call Balances Progress and Risk
PremiumCompany Announcements
Inmune Bio Earnings Call Balances Progress and Risk
16d ago
INMB
INMB Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
INMB Upcoming Earnings Report: What to Expect?
20d ago
INMB
INmune Bio’s MINDFuL trial presented as succesful example in Alzheimer’s
PremiumThe Fly
INmune Bio’s MINDFuL trial presented as succesful example in Alzheimer’s
29d ago
INMB
INmune Bio upgraded to Buy from Neutral at Lucid Capital
PremiumThe Fly
INmune Bio upgraded to Buy from Neutral at Lucid Capital
1M ago
INMB
Inmune Bio Completes Early INKmune Trial in Advanced Prostate Cancer: What Investors Should Watch Next
PremiumCompany AnnouncementsInmune Bio Completes Early INKmune Trial in Advanced Prostate Cancer: What Investors Should Watch Next
2M ago
INMB
INmune Bio Highlights CORDStrom RDEB Program and IP Strength
Premium
Company Announcements
INmune Bio Highlights CORDStrom RDEB Program and IP Strength
2M ago
8K
INMB
INmune Bio Advances XPro Toward Registrational Alzheimer’s Study
Premium
Company Announcements
INmune Bio Advances XPro Toward Registrational Alzheimer’s Study
2M ago
8K
INMB
INmune Bio to Present New CORDStrom Phase III Data
PremiumCompany Announcements
INmune Bio to Present New CORDStrom Phase III Data
2M ago
8K
INMB
INmune Bio Advances CORDStrom Toward Rare Disease Commercialization
PremiumCompany Announcements
INmune Bio Advances CORDStrom Toward Rare Disease Commercialization
2M ago
8K
INMB
INmune Bio: Biomarker-Driven Alzheimer’s Trial Design and Pipeline Catalysts Underpin Buy Rating
PremiumRatings
INmune Bio: Biomarker-Driven Alzheimer’s Trial Design and Pipeline Catalysts Underpin Buy Rating
2M ago
INMB
INmune Bio announces FDA alignment on phase 2b/3 registration pathway
PremiumThe Fly
INmune Bio announces FDA alignment on phase 2b/3 registration pathway
2M ago
INMB
INmune Bio submits pre-submission package for CORDStrom with MHRA
PremiumThe FlyINmune Bio submits pre-submission package for CORDStrom with MHRA
2M ago
INMB
INmune Bio: Undervalued Pipeline with 2026 Clinical and Regulatory Catalysts Driving Buy Rating
Premium
Ratings
INmune Bio: Undervalued Pipeline with 2026 Clinical and Regulatory Catalysts Driving Buy Rating
3M ago
INMB
INmune Bio outlines 2026 regulatory path in shareholder letter
Premium
Company Announcements
INmune Bio outlines 2026 regulatory path in shareholder letter
3M ago
8K
INMB
INmune Bio CEO says ‘well positioned for continued execution’
PremiumThe Fly
INmune Bio CEO says ‘well positioned for continued execution’
3M ago
INMB
Inmune Bio Amends April 2024 Investor Warrants
PremiumCompany Announcements
Inmune Bio Amends April 2024 Investor Warrants
4M ago
8K
INMB
INmune Bio Establishes $65 Million At-The-Market Offering
PremiumCompany Announcements
INmune Bio Establishes $65 Million At-The-Market Offering
4M ago
8K
INMB
Inmune Bio Ends Sales Agreement with RBC and BTIG
PremiumCompany Announcements
Inmune Bio Ends Sales Agreement with RBC and BTIG
4M ago
8K
INMB
Inmune Bio Unveils Promising Alzheimer’s Trial Data
PremiumCompany AnnouncementsInmune Bio Unveils Promising Alzheimer’s Trial Data
4M ago
8K
INMB
INmune Bio publishes study on INmune’s CORDStrom platform
Premium
The Fly
INmune Bio publishes study on INmune’s CORDStrom platform
4M ago
INMB
Inmune Bio Updates Executive Employment Agreements
Premium
Company Announcements
Inmune Bio Updates Executive Employment Agreements
4M ago
8K
INMB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >